`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`___________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________
`SAWAI USA, INC. AND SAWAI PHARMACEUTICAL CO., LTD.,
`Petitioners,
`v.
`BIOGEN MA INC.,
`Patent Owner.
`____________________________________________
`IPR2019-00789
`U.S. Patent No. 8,399,514
`____________________________________________
`
`
`
`PATENT OWNER’S MANDATORY NOTICES
`
`
`

`

`Patent Owner’s Mandatory Notices
`Case No. IPR2019-00789
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Biogen MA Inc. provides
`
`
`
`the following mandatory notices.
`
`I.
`
`Real Party-in-Interest - 37 C.F.R. § 42.8(b)(1)
`The real party-in-interest is Biogen MA Inc., the owner of U.S. Patent No.
`
`8,399,514 (“the ’514 patent”). A corporate name change document was recorded in
`
`the U.S. Patent and Trademark Office on April 27, 2015 (reel 035507/frame 0541)
`
`and May 4, 2015 (reel 035571/frame 0926). Those documents changed the corporate
`
`name from Biogen Idec MA Inc. to Biogen MA Inc. The original assignment to
`
`Biogen Idec MA Inc. of U.S. Patent Application No. 13/372,426 that led to the ’514
`
`patent was recorded in the Office on May 3, 2012 (reel 028146/frame 0980).
`
`II. Related Matters - 37 C.F.R. § 42.8(b)(2)
`The ’514 patent is currently involved in the following federal cases:
`
`Biogen International GmbH and Biogen MA Inc. v. Amneal Pharmaceuticals
`LLC et al., C.A. No. 17-823-LPS (D. Del.) (Consolidated)
`
`
`Biogen International GmbH and Biogen MA Inc. v. Mylan Pharmaceuticals
`Inc., C.A. No. 17-116-IMK (N.D. W.Va.)
`
`
`The ’514 patent is currently involved in the following proceeding before the
`
`PTAB:
`
`Mylan Pharmaceuticals Inc. v. Biogen MA Inc., IPR2018-01403.
`
`The ’514 patent has also been involved in the following proceedings before
`
`the PTAB:
`
`2
`
`

`

`
`Coalition for Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01136 (McK)
`
`Patent Owner’s Mandatory Notices
`Case No. IPR2019-00789
`
`Coalition for Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01993 (RES)
`
`Biogen MA Inc. v. Forward Pharma A/S, Intf. No. 106,023 (RES), aff’d, No. 2017-
`
`2109 (Fed. Cir. Oct. 24, 2018), reh’g denied, No. 2017-2109 (January 2, 2019)
`
`The following U.S. Applications claim benefit of priority to the application
`
`that issued as the ’514 patent: 13/767,014 (abandoned), 13/804,283 (abandoned),
`
`14/718,962 (abandoned), 15/959,651 (abandoned), 15/983,837 (abandoned),
`
`15/988,578 (abandoned), 16/221,172 (pending) and 16/238,724 (pending).
`
`Patent Owner is not aware of any other related matters that would affect or be
`
`affected by this proceeding.
`
`III. Lead and Back-up Counsel - 37 C.F.R. § 42.8(b)(3)
`
`Lead Counsel
`Barbara C. McCurdy
`Reg. No. 32,120
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 408-4047
`barbara.mccurdy@finnegan.com
`
`Back-Up Counsel
`Mark J. Feldstein
`Reg. No. 46,693
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 408-4092
`mark.feldstein@finnegan.com
`
`Erin M. Sommers
`Reg. No. 60,974
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`
`3
`
`

`

`Patent Owner’s Mandatory Notices
`Case No. IPR2019-00789
`
`
`
`(202) 408-4292
`erin.sommers@finnegan.com
`
`Pier D. DeRoo (Reg. No. 69,340)
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 408-4418
`pier.deroo@finnegan.com
`
`IV. Power of Attorney - 37 C.F.R. § 42.10(b)
`Pursuant to 37 C.F.R. § 42.10(b), Patent Owner confirms that the enclosed
`
`power of attorney for U.S. Application No. 13/372,426 (issued as the ’514 patent)
`
`from Biogen MA Inc. to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`
`(Customer Number 22,852), which includes Barbara C. McCurdy, Mark J. Feldstein,
`
`Erin M. Sommers, and Pier D. DeRoo, was previously filed with the USPTO on
`
`April 27, 2015 in Interference No. 106,023. See Appx. A.
`
`V.
`
`Service Information
`Please send all correspondence to the lead counsel at the address shown above.
`
`Under 37 C.F.R. § 42.6(e), Patent Owner consents to electronic service by e-mail to
`
`the following e-mail addresses:
`
`barbara.mccurdy@finnegan.com;
`
`mark.feldstein@finnegan.com
`
`erin.sommers@finnegan.com; and
`
`4
`
`

`

`Patent Owner’s Mandatory Notices
`Case No. IPR2019-00789
`
`pier.deroo@finnegan.com.
`
`
`
`
`
`
`Dated: March 25, 2019
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`By: / Barbara C. McCurdy /
`Barbara C. McCurdy, Reg. No. 32,120
`Finnegan, Henderson, Farabow, Garrett
` & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`(202) 408-4047
`Counsel for Patent Owner
`
`5
`
`

`

`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s
`
`Mandatory Notices was served electronically via e-mail on March 25, 2019, in its
`
`entirety on the following:
`
`Brian Sodikoff
`Katten Muchin Rosenman LLP
`525 West Monroe Street
`Chicago, IL 60661-3693
`Telephone: (312) 902-5462
`E-mail: brian.sodikoff@kattenlaw.com
`
`Christopher B. Ferenc
`Katten Muchin Rosenman LLP
`2900 K Street NW
`North Tower - Suite 200
`Washington, DC 20007
`Telephone: (202) 625-3647
`E-mail: Christopher.ferenc@kattenlaw.com
`
`Petitioner has agreed to electronic service.
`
`Dated: March 25, 2019
`
`By: / Catherine A. Sadler /
`Catherine A. Sadler
`Case Manager
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`
`
`
`

`

`PTOISBI81 (01-09)
`Approved for use through 1113012011. OMEI 0651-0035
`US. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act Of 1995, no persons are required to respond to a coilectton Of information unless it displays a valid OMB control number.
`
`POWER OF ATTORNEY
`13/372,425
`APP“°a“°" “umber
`
`OR
`Filing Date
`February 13,2012
`
`First Named Inventor
`Matvey E. LUKASHEV
`
`R233%?fivaogopfinggngfigTSNI-ENYEY Title
`Treatment of Multiple Sclerosis
`
`AN D
`Art Unit
`CHANGE OF CORRESPONDENCE ADDRESS Examiner “am”
`Attorney Docket Number
`
`
`
`John ULM
`
`A Power of Attorney is submitted herewith.
`OR
`
`
`
`I hereby appoint Practitioner(s) associated with the following Customer
`Number as myiour attorneyts) or agent(s} to prosecute the application
`identified above, and to transact all business in the United States Patent
`and Trademark Office connected therewith:
`OR
`I hereby appoint Practitioner(s) named below as myiour attorney(s) or agentts) to prosecute the apptication identified above, and
`to transact all business in the United States Patent and Trademark Office connected therewith:
`
`I
`22 852
`
`Practitioner(s) Name
`
`Registration Number
`
`
`
`
`
`
`
`i i I I
`
`Please recognize or Change the correspondence address for the above~identified application to:
`
`The address associated with the abovementioned Customer Number.
`OR
`
`CI
`
`22,852
`The address associated with Customer Number:
`OR
`
`Firm or
`Individual Name
`Address
`
`Country
`
`
`
`
`
`City
`
`
`
`
`
`
`Telephone
`lam the:
`
`D Applicantilnventor.
`OR
`Assignee of record of the entire interest. See 37 CFR 3.71.
`
`
`Statement under 37 CFR 3. 73(1)) (Form PTO/SB/QG) submitted herewith or flied on
`
`EGNATURE of Applicant or Assignee of Record
`it Fri
`'i ui I
`CARA LOWEN
`Date
`Signature
`(am ?
`i
`j’h’L 1015
`
`ASSISTANT SEQREM Telephone Tfii
`Name
`_L(__Q_/_O ,
`Title and Company
`
`NOTE: Signatures of all the inventors or assignees Oi resend"
`signature is required! see beioW‘“.
`
`forms are submitted.
`II *Total of
`This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to Obtain or retain a benefit by the public which is to file (and by the
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C, 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to compiete,
`including gathering, preparing. and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on
`the amount of time you require to complete this form andior suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`.Trademark Office, us. Department Of Commerce, P.O. Box 1450, Alexandria, VA 22313—1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS
`ADDRESS. SEND To: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`if you need assistance in completing the form, calf 1-800-PTO-9199 and select option 2.
`
`